In the context of immunotherapy, synergistic effects of PD-1/PD-L1 checkpoint inhibitors and vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) have been demonstrated, and combination therapy improves tumor response, as well as improves overall survival of gastric cancer patients60. Here, KDR is linked to gastric cancer.